TITLE

Drug sales

PUB. DATE
July 2005
SOURCE
CMAJ: Canadian Medical Association Journal;7/19/2005, Vol. 173 Issue 2, p141
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the increase in the sale of patented drugs in Canada in 2004. Research and development spending according to patentees.
ACCESSION #
17557280

 

Related Articles

  • Ways to Recover Lost Margins. Brandyberry, Gregg // BioPharm International;Apr2012, Vol. 25 Issue 4, p22 

    The article offers information on recovering margins in the pharmaceutical industry. It states that the margins were lost because of more costly and less productive research and development (R&D)greater drug-failure rates and shorter patent life. It mentions that audit reduces waste, corrects...

  • Value of pharmaceuticals: ensuring the future of research and development. Serajuddin, Hamida K.; Serajuddin, Abu T. M. // Journal of the American Pharmacists Association: JAPhA;Jul/Aug2006, Vol. 46 Issue 4, p511 

    Objective: To analyze the current situation under which the pharmaceutical industry is criticized for the production of drugs with potential adverse effects, the high prices of medicines, and aggressive marketing practices, and to provide a proposal to rectify the...

  • Changing Models. Jawadekar, Mak // Contract Pharma;Sep2013, Vol. 15 Issue 7, p36 

    The article discusses the role of outsourcing to the research and development (R&D) manufacturing of pharma industry. It mentions that outsourcing improves the R&D productivity and work efficiency of the sector. It notes that the competitive manufacturing forces the sector to streamline its...

  • Drug Abuse. Thompson, Nicholas // New Republic;10/7/2002, Vol. 227 Issue 15, p18 

    Criticizes the pharmaceutical industry in the U.S. for its inability to develop innovative drugs due to its focus on marketing rather than on research. Findings of a National Institute for Health Care Management report on the production of innovative drugs; Response of the Pharmaceutical...

  • Preface. Reitz, Allen B. // Current Topics in Medicinal Chemistry;Jan2012, Vol. 12 Issue 1, p1 

    The author addresses the changes within the pharmaceutical industry and medicinal chemistry. He notes that 22 of the top 25 selling drugs are generic and lack the composition of matter patent protection that characterizes the early phase of the life cycle for any successful new product launch in...

  • Industry Forecast Scenario.  // Canada Pharma & Healthcare Report;Q4 2011, Issue 4, p38 

    The article forecasts the growth of Canada's pharmaceuticals industry covering the overall market and the markets for prescription drugs, patented drugs, generics drugs, over-the-counter drugs and medical devices. Economic indicators point to positive growth prospects for the economy. The key...

  • Blockbuster Drug Numbers Increase. Scott, Alex // Chemical Week;4/5/2006, Vol. 168 Issue 12, p31 

    The article reports on the increase in the number of blockbuster drugs in 2005, according to a survey by market research firm IMS Health. Six blockbusters are expected to lose their patents in 2006, although the launch of new products and continued growth of those already on the market into...

  • The 'patent cliff' looms large for Big Pharma.  // Australian Journal of Pharmacy;Jan2010, Vol. 91 Issue 1076, p40 

    The article reports on the expiration of patents within the pharmaceutical industry. It states patent expiries within the industry intensifies from 2011 onwards that affects some of the biggest brands in the industry such as Pfizer Inc.'s Lipitor which will drive down revenue growth. It notes...

  • How to improve R&D productivity: the pharmaceutical industry's grand challenge. Paul, Steven M.; Mytelka, Daniel S.; Dunwiddie, Christopher T.; Persinger, Charles C.; Munos, Bernard H.; Lindborg, Stacy R.; Schacht, Aaron L. // Nature Reviews Drug Discovery;Mar2010, Vol. 9 Issue 3, p203 

    The pharmaceutical industry is under growing pressure from a range of environmental issues, including major losses of revenue owing to patent expirations, increasingly cost-constrained healthcare systems and more demanding regulatory requirements. In our view, the key to tackling the challenges...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics